Schroder Investment Management Group Vertex Pharmaceuticals Inc Transaction History

Schroder Investment Management Group

$94.5 Billion
Q3 2024

A detailed history of Schroder Investment Management Group transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Schroder Investment Management Group holds 205,779 shares of VRTX stock, worth $84 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

205,779

Previous 228,819 10.07%

Holding current value

$84 Million

Previous $107 Million 10.77%

% of portfolio

0.1%

Previous 0.12%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $10.6 Million - $11.7 Million	-23,040 Reduced 10.07%	205,779 $95.7 Million
Q2 2024 Aug 12, 2024	BUY	$392.81 - $485.53 $8.06 Million - $9.97 Million	20,531 Added 9.86%	228,819 $107 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $10.1 Million - $11 Million	-24,692 Reduced 10.6%	208,288 $87.1 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $13.6 Million - $16.3 Million	39,712 Added 20.55%	232,980 $94.8 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $569,495 - $610,382	-1,684 Reduced 0.86%	193,268 $67.2 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $5.24 Million - $5.86 Million	16,657 Added 9.34%	194,952 $68.6 Million
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $6.11 Million - $6.97 Million	-21,566 Reduced 10.79%	178,295 $56.2 Million
Q4 2022 Feb 10, 2023	BUY	$285.76 - $321.48 $26 Million - $29.2 Million	90,908 Added 83.44%	199,861 $57.7 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $14.9 Million - $16.7 Million	54,563 Added 100.32%	108,953 $31.5 Million
Q2 2022 Aug 11, 2022	SELL	$234.96 - $292.55 $1.61 Million - $2.01 Million	-6,863 Reduced 11.2%	54,390 $15.2 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $3.4 Million - $4.01 Million	15,359 Added 33.47%	61,253 $15.7 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $227,457 - $287,133	-1,285 Reduced 2.72%	45,894 $10.1 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $524,398 - $586,844	2,891 Added 6.53%	47,179 $8.56 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $3.44 Million - $4.05 Million	18,328 Added 70.6%	44,288 $8.93 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $83,015 - $96,765	401 Added 1.57%	25,960 $5.58 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $309,065 - $412,202	-1,493 Reduced 5.52%	25,559 $6.04 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $14 Million - $16.6 Million	-54,791 Reduced 66.95%	27,052 $7.06 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $16.1 Million - $21.1 Million	71,250 Added 672.61%	81,843 $23.8 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $290,865 - $360,811	-1,456 Reduced 12.08%	10,593 $2.7 Million
Q4 2019 Feb 11, 2020	SELL	$166.71 - $223.91 $6.48 Million - $8.71 Million	-38,880 Reduced 76.34%	12,049 $2.64 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $7.71 Million - $8.68 Million	46,382 Added 1020.06%	50,929 $8.49 Million
Q2 2019 Aug 08, 2019	SELL	$164.61 - $190.37 $4.9 Million - $5.67 Million	-29,775 Reduced 86.75%	4,547 $834,000
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $8,350 - $9,929	-51 Reduced 0.15%	34,322 $6.31 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $112,109 - $141,850	738 Added 2.19%	34,373 $5.7 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $1.06 Million - $1.22 Million	6,326 Added 23.16%	33,635 $6.48 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $269,436 - $314,256	1,849 Added 7.26%	27,309 $4.03 Million
Q1 2018 May 11, 2018	BUY	$151.6 - $177.13 $197,080 - $230,269	1,300 Added 5.38%	25,460 $4.15 Million
Q3 2017 Nov 09, 2017	BUY	$148.13 - $162.24 $3.58 Million - $3.92 Million	24,160	24,160 $3.62 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

News

Stay updated on Schroder Investment Management Group with notifications on news.

Account

Schroder Investment Management Group Vertex Pharmaceuticals Inc Transaction History